hydroxychloroquine has been researched along with Local Neoplasm Recurrence in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 7.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 3.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| "Hydroxychloroquine (HCQ) is an autophagy inhibitor." | 3.01 | SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. ( Bahary, N; Boone, BA; Fei, N; Hogg, ME; Lotze, MT; Ramanathan, R; Singhi, AD; Wen, S; Zeh, HJ; Zureikat, AH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| De Sanctis, JB | 1 |
| Charris, J | 1 |
| Blanco, Z | 1 |
| Ramírez, H | 1 |
| Martínez, GP | 1 |
| Mijares, MR | 1 |
| Spezzani, V | 1 |
| Piunno, A | 1 |
| Iselin, HU | 1 |
| Zhao, J | 1 |
| Zhou, W | 1 |
| Wu, Y | 1 |
| Ji, P | 1 |
| Yang, L | 1 |
| Yan, X | 1 |
| Zhang, Z | 1 |
| Fei, N | 1 |
| Wen, S | 1 |
| Ramanathan, R | 1 |
| Hogg, ME | 1 |
| Zureikat, AH | 1 |
| Lotze, MT | 1 |
| Bahary, N | 1 |
| Singhi, AD | 1 |
| Zeh, HJ | 1 |
| Boone, BA | 1 |
| Zhao, Z | 1 |
| Wu, J | 1 |
| Liu, X | 1 |
| Liang, M | 1 |
| Zhou, X | 1 |
| Ouyang, S | 1 |
| Yao, J | 1 |
| Wang, J | 2 |
| Luo, B | 1 |
| Garbutt, C | 1 |
| Ma, H | 1 |
| Gao, P | 1 |
| Hornicek, FJ | 1 |
| Kan, Q | 1 |
| Shi, H | 1 |
| Duan, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity[NCT02320630] | 240 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for hydroxychloroquine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Human | 2021 |
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Pancreatic Ductal; Disea | 2021 |
4 other studies available for hydroxychloroquine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Neoplasm Recurrence, Local; Signal Transduct | 2023 |
Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple.
Topics: Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Breast Neoplasms; Cobicistat; Coronavirus | 2020 |
Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolife | 2018 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Movement; | 2018 |